GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans
James M Luther, Justina Ray, Dawei Wei, John R Koethe, Latoya Hannah, Anthony DeMatteo, Robert Manning, Andrew S Terker, Dungeng Peng, Hui Nian, Chang Yu, Mona Mashayekhi, Jorge Gamboa, Nancy J Brown, James M Luther, Justina Ray, Dawei Wei, John R Koethe, Latoya Hannah, Anthony DeMatteo, Robert Manning, Andrew S Terker, Dungeng Peng, Hui Nian, Chang Yu, Mona Mashayekhi, Jorge Gamboa, Nancy J Brown
Abstract
[Figure: see text].
Keywords: eicosanoids; epoxide hydrolases; hypertension; insulin resistance; oxidative stress.
Figures
CONSORT Study enrollment flow-diagram.
A) Glucose concentration was maintained near a target of 95 mg/dL during Placebo (●) and GSK2256294 (▼). Grey shading indicates insulin infusion rates during low and high dose insulin (in mU/m2/min). B) The glucose infusion rate normalized to fat-free mass [FFM] (GIR) and C) insulin concentrations were similar during euglycemic-hyperinsulinemic clamp after one-week treatment with placebo or GSK2256294. Data are mean±SEM. *P<0.05, ***P≤0.001.
Source: PubMed